China’s 2025 NRDL Negotiated Drugs See Both Procurement Value and Volume Rise: Report

The dual rise in both value and volume for the vast majority of negotiated drugs suggests that NRDL inclusion is translating into genuine clinical uptake rather than volume gains offset by price concessions — a meaningful signal for the economics of China's reimbursement-driven market access model. The finding matters most for manufacturers weighing whether negotiated entry delivers durable revenue, and for payers tracking whether dynamic adjustments since 2018 are balancing access against budget. Whether this value-and-volume pattern holds as the negotiated pool continues to expand is the open question.